Stephen D. Griffin serves as Executive Vice President, Chief Financial Officer, and Treasurer at Anika Therapeutics, Inc., a global medical technologies company specializing in therapeutics for osteoarthritis pain management, regenerative medicine, and advanced wound care. In this role, which he assumed in October 2021, Griffin oversees all financial operations, including strategic planning, capital allocation, investor relations, and treasury functions. He plays a pivotal role in driving Anika's financial strategy to support global expansion, product innovation, and sustainable growth amid a dynamic healthcare landscape. With over 25 years of experience in the biotechnology and pharmaceutical industries, Griffin brings a proven track record of financial leadership. Prior to Anika, he served as Chief Financial Officer at Organogenesis Holdings, Inc., from January 2020 to October 2021, where he spearheaded the company's successful public listing through a SPAC merger valued at over $1 billion. Before that, he held progressive finance roles at Shire plc (now Takeda), including Vice President and Head of Finance for Regenerative Medicine from 2017 to 2020, and at Genzyme Corporation (acquired by Sanofi) from 2005 to 2017, rising to Senior Director of Financial Planning and Analysis. His early career began at Deloitte & Touche, where he honed his expertise in audit and advisory services for life sciences clients. Griffin's achievements include orchestrating complex financings, mergers, and acquisitions, optimizing operational efficiencies, and navigating regulatory environments to deliver shareholder value. A Certified Public Accountant, he holds a Bachelor of Science in Accounting from Boston College. His strategic acumen has been instrumental in positioning Anika for long-term success through prudent financial management and innovative capital strategies.